Your browser doesn't support javascript.
loading
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz, Matthew H G; Petroni, Gina R; Bauer, Todd; Reilley, Matthew J; Wolpin, Brian M; Stucky, Chee-Chee; Bekaii-Saab, Tanios S; Elias, Rawad; Merchant, Nipun; Dias Costa, Andressa; Lenehan, Patrick; Cardot-Ruffino, Victoire; Rodig, Scott; Pfaff, Kathleen; Dougan, Stephanie K; Nowak, Jonathan Andrew; Varadhachary, Gauri R; Slingluff, Craig L; Rahma, Osama.
Affiliation
  • Katz MHG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA mhgkatz@mdanderson.org.
  • Petroni GR; Division of Translational Research and Applied Statistics, Department of Public Health Sciences, University of Virginia Health System, Charlottesville, Virginia, USA.
  • Bauer T; Department of Surgery, University of Virginia Health System, Charlottesville, Virginia, USA.
  • Reilley MJ; Division of Hematology and Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
  • Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Stucky CC; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Bekaii-Saab TS; Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
  • Elias R; Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clin, Phoenix, Arizona, USA.
  • Merchant N; Hartford HealthCare Cancer Institute, Plainville, Connecticut, USA.
  • Dias Costa A; Department of Surgery, University of Miami, Coral Gables, Florida, USA.
  • Lenehan P; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
  • Cardot-Ruffino V; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Rodig S; Department of Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  • Pfaff K; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Dougan SK; Department of Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  • Nowak JA; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Varadhachary GR; Department of Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  • Slingluff CL; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Rahma O; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
J Immunother Cancer ; 11(12)2023 12 01.
Article in En | MEDLINE | ID: mdl-38040420
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Carcinoma, Pancreatic Ductal Limits: Humans Language: En Journal: J Immunother Cancer Year: 2023 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Carcinoma, Pancreatic Ductal Limits: Humans Language: En Journal: J Immunother Cancer Year: 2023 Type: Article Affiliation country: United States